<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515368</url>
  </required_header>
  <id_info>
    <org_study_id>PETVACC</org_study_id>
    <secondary_id>15/LO/2039</secondary_id>
    <secondary_id>191407</secondary_id>
    <nct_id>NCT04515368</nct_id>
  </id_info>
  <brief_title>A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity</brief_title>
  <acronym>PETVACC</acronym>
  <official_title>A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study forms part of an integrated, multi-study effort to identify potential biomarkers&#xD;
      of reactogenicity to vaccines. We have selected PET-CT as it is in routine clinical use and&#xD;
      has been serendipitously shown to image lymph nodes and injection site inflammation after&#xD;
      immunisation.The study's objectives are exploratory:&#xD;
&#xD;
        1. To methodically characterise relative anatomical distribution and intensity of&#xD;
           post-immunisation innate immune activation visualised by PET-CT after immunisation with&#xD;
           adjuvanted and non-adjuvanted vaccines.&#xD;
&#xD;
        2. To correlate PET/CT changes with diary card recorded symptoms of reactogenicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2016</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">September 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18FDG-PET/CT imaging</measure>
    <time_frame>4 hours</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18FDG- or 11C-PBR28-PET/CT imaging</measure>
    <time_frame>1 day</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18FDG- or 11C-PBR28-PET/CT imaging</measure>
    <time_frame>3 days</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18FDG- or 11C-PBR28-PET/CT imaging</measure>
    <time_frame>5 days</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18FDG- or 11C-PBR28-PET/CT imaging</measure>
    <time_frame>7 days</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18FDG-PET/CT imaging</measure>
    <time_frame>10 days</time_frame>
    <description>Quantification of PET activity at injection site and draining lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diary card of reactogenicity</measure>
    <time_frame>0 to 10 days</time_frame>
    <description>Recording of solicited and unsolicited adverse events after immunisation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <condition>Immunization Reaction</condition>
  <arm_group>
    <arm_group_label>Fendrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fendrix (Hepatitis B surface antigen adjuvanted by AS04C containing 3¬≠O¬≠desacyl¬≠4'¬≠ monophosphoryl lipid A adsorbed on aluminium phosphate, GlaxoSmithKline; 0.5 mL. intramuscular. stat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bexsero</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bexsero (Meningococcal group B subunit / Outer Membrane Vesicles, GlaxoSmithKline); 0.5 mL. intramuscular. stat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluad (split virion inactivated seasonal trivalent influenza vaccine adjuvanted with MF59C, Northern Hemisphere 2016-17, Seqirus Vaccines and Diagnostics) 0.5 mL. intramuscular. stat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seasonal Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seasonal Trivalent Influenza Vaccine ('ÄòSTIV'Äô, split virion inactivated, Northern Hemisphere 2016-17, Sanofi Pasteur); 0.5 mL. intramuscular. stat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunization</intervention_name>
    <description>Immunisation with one of four licensed vaccines</description>
    <arm_group_label>Bexsero</arm_group_label>
    <arm_group_label>Fendrix</arm_group_label>
    <arm_group_label>Fluad</arm_group_label>
    <arm_group_label>Seasonal Trivalent Influenza Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read and understand the informed consent form (ICF), and understand study&#xD;
             procedures&#xD;
&#xD;
          2. Signed the ICF&#xD;
&#xD;
          3. Healthy male aged 18'Äì55 years inclusive&#xD;
&#xD;
          4. BMI 19'Äì27 kg/m2&#xD;
&#xD;
          5. Pre-immunised with hepatitis B vaccine on the basis of immunisation history if Fendrix&#xD;
             or Engerix B is to be the study vaccine&#xD;
&#xD;
          6. Available for follow-up for the duration of the study&#xD;
&#xD;
          7. Is, in the opinion of the investigator, healthy on the basis of a medical history,&#xD;
             symptom directed medical examination and vital signs&#xD;
&#xD;
          8. Have not undergone research radiation exposures, and agree to avoid such exposures,&#xD;
             for 12 months before/after this study&#xD;
&#xD;
          9. Be willing to avoid vigorous exercise or contact sports between vaccination and PET&#xD;
             scan (e.g. gym workouts, prolonged cycling, rowing, martial arts or rugby)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to any of the vaccine components or a history of any&#xD;
             allergy that in the opinion of the investigator would contraindicate participant&#xD;
             participation&#xD;
&#xD;
          2. Use of steroids or immunosuppressive/immunomodulating drugs either orally or&#xD;
             parenterally within 3 months of the PET scan. (Topical/ocular/nasal/inhaled steroids&#xD;
             are allowed.)&#xD;
&#xD;
          3. Expression of only TSPO with low-affinity to PBR28, on the basis of TSPO genotype&#xD;
&#xD;
          4. Currently participating in a clinical study with a drug or device&#xD;
&#xD;
          5. Any condition that, in the investigator'Äôs opinion, compromises the participant'Äôs&#xD;
             ability to meet protocol requirements or to complete the study&#xD;
&#xD;
          6. Unable to read and speak English to a fluency level adequate for the full&#xD;
             comprehension of procedures required in participation and consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David JM Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College Healthcare NHS Trust</affiliation>
  </overall_official>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

